Elicio Therapeutics Appoints Marc J. Wolfgang As Chief Technology Officer, Bringing 30+ Years Of Biopharma Leadership In Cell Therapy, RNA Medicines, And Biologics

Elicio Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, announced the appointment of Marc J. Wolfgang, M.S., as Chief Technology Officer. Mr. Wolfgang brings over 30 years of leadership experience in the biopharmaceutical industry, with extensive expertise spanning manufacturing, CMC strategy, development, quality, and supply chain management across multiple therapeutic modalities, including cell therapy, biologics, nucleic-acid medicines, vaccines, and lipid nanoparticle platforms. 

Most recently, he served as Senior Vice President of Technical Development and Operations at Sail Biomedicines, where he led all development, manufacturing, analytical, and quality functions. Prior to that, he was Vice President of U.S. Manufacturing at BioNTech, overseeing manufacturing and supply chain operations for cell and gene therapy programs. 

Earlier in his career, Mr. Wolfgang held senior CMC and operations roles at companies including Cerulean Pharma, Momenta Pharmaceuticals, Millennium Pharmaceuticals, Biogen, and Boehringer Ingelheim, where he built and scaled manufacturing organizations, led global technology transfers, and established end-to-end supply chains for clinical and commercial products.

Robert T. Connelly, President and Chief Executive Officer of Elicio, said that Mr. Wolfgang is an exceptional leader in CMC strategy and operations with deep experience guiding innovative therapeutic platforms from early development through commercial readiness. He added that as Elicio prepares for potential late-stage development and commercial-scale execution of ELI-002 7P, as well as advancement of its other pipeline assets, Mr. Wolfgang’s expertise in cell therapy, RNA-based medicines, and other complex modalities is well aligned with the company’s strategic priorities. Connelly expressed enthusiasm about welcoming him to the executive team at this critical stage for the company.

Commenting on his appointment, Mr. Wolfgang said he is delighted to join Elicio at such a pivotal time, ahead of the anticipated ELI-002 7P event-driven primary disease-free survival analysis in the first half of 2026. He highlighted the company’s lymph node–targeted platform as a powerful approach to enhancing and directing immune responses and expressed his commitment to building the technical and operational infrastructure that will support Elicio’s next phase of clinical development and growth.

Mr. Wolfgang holds a Master of Science in Chemistry from Montclair State University, a Bachelor of Science in Biology (Genetics) from Pennsylvania State University, and a Biopharma Executive Leadership Certificate from Babson College. He previously served as Chairman of the Nanomedicines Alliance and has collaborated extensively with the U.S. Food and Drug Administration and the National Institutes of Health on nanotechnology, manufacturing, and regulatory policy initiatives.